Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

November 5, 2019

Genetic Variations of Glucocorticoid Receptor May Explain Loss of Muscle Strength in Cushing’s, Study Says

News

Genetic variations in the glucocorticoid receptor may explain why some patients with Cushing’s syndrome lose muscle strength, a study suggests. The study, “Glucocorticoid receptor polymorphisms influence muscle strength in ... Read more

September 26, 2019September 26, 2019

Recorlev Leads to Sustained Improvements in Cortisol Control in Cushing’s Syndrome, Phase 3 Trial Shows

News

The oral investigational treatment Recorlev (levoketoconazole) leads to sustained improvements in the control of cortisol among patients with endogenous Cushing’s syndrome, a Phase 3 trial shows. The trial’s findings were ... Read more

May 22, 2019May 22, 2020

Growth Delays Plus Rapid Weight Gain in Children May Signal Cushing’s

News

Cushing’s syndrome should be suspected in children and adolescents with evident growth delays, and signs of rapid weight gain, depression, anxiety, and hyperandrogenism, a study finds. While brain surgery to ... Read more

May 14, 2019

Signifor Normalizes Cortisol Levels in Cushing’s Disease Patients, Real-world Study Shows

News

In real-life clinical practice, Novartis‘ Signifor (pasireotide) completely or nearly normalizes the levels of cortisol in the urine of patients with mild to moderate Cushing’s disease, a study says. ... Read more

May 9, 2019

Strongbridge Prepares to Submit New Drug Application for Recorlev

News

Strongbridge Biopharma is preparing the submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking the approval of Recorlev (levoketoconazole) for the treatment of ... Read more

May 2, 2019

Strongbridge’s Recorlev Alleviates Symptoms of Cushing’s Syndrome, Eases Depression, Study Shows

News

Strongbridge Biopharma’s Recorlev (levoketoconazole) alleviates clinical signs and symptoms of Cushing’s syndrome that may cause discomfort and distress to patients, a Phase 3 trial shows. The trial’s findings were presented ... Read more

March 28, 2019

Recorlev Continues to Show Meaningful Improvements, Phase 3 Trial Shows

News

Strongbridge Biopharma‘s Recorlev (levoketoconazole) continues to show clinically meaningful improvements in the control of cortisol among patients with endogenous Cushing’s syndrome, a Phase 3 clinical trial shows. Cushing’s syndrome is caused ... Read more

March 21, 2019

Recorlev Safe, Effective Over Long Term for Treatment of Cushing’s, Phase 3 Data Suggest

News

Long-term treatment with Strongbridge Biopharma‘s Recorlev (levoketoconazole) continues to be well-tolerated and to induce clinically meaningful improvements in endogenous Cushing’s syndrome patients, an extended evaluation of a Phase 3 clinical trial shows. Cushing’s ... Read more

November 8, 2018November 8, 2018

Measuring Pituitary Gland Hormone with BIPSS in Children Not as Accurate as Previously Thought, Study Finds

News

Bilateral inferior petrosal sinus sampling (BIPSS) — a diagnostic technique for Cushing’s disease that measures the levels of the adrenocorticotropic hormone (ACTH) hormone produced by the pituitary gland — is not as accurate ... Read more

September 13, 2018

Too Many Inflammatory Molecules Increase Risk of Heart Disease in Subclinical Cushing’s, Study Shows

News

High levels of inflammatory cytokines — molecules that mediate the body’s immune response — may increase the risk of metabolic and heart disease in subclinical Cushing’s syndrome patients, a retrospective ... Read more